<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; SEPR</title>
	<atom:link href="http://www.stockbloghub.com/tag/sepr/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Thu, 24 May 2012 23:16:35 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(SEPR) Top Small-Cap Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731</link>
		<comments>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731#comments</comments>
		<pubDate>Sat, 17 Oct 2009 00:04:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Charles River Laboratories International Inc]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17731</guid>
		<description><![CDATA[Today we are featuring top-performing “Small-Cap&#8221; equity mutual funds, which primarily invest in equity securities of companies that have market capitalizations of less than $2 billion. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Small-Cap Equity Funds. 2 Solid Picks Dean Small Cap Value A (DASCX) seeks long-term capital appreciation and secondarily, dividend income. The fund focuses on high-quality companies that are undervalued for transitory reasons in search of above-average returns. The fund may invest in equity securities of mid or large-cap companies, preferred stocks, or derivative instruments, such as put and call options and futures contracts, and in fixed-income securities Incorporatedluding corporate bonds. Unit holders have to make a minimum initial investment of $1,000 to enter this Zacks#1 Rank (“Strong Buy&#8221;) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/16/sepr-top-small-cap-equity-funds-mutual-fund-commentary-2/17731/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Dainippon-Sepracor Deal Emerges</title>
		<link>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778</link>
		<comments>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778#comments</comments>
		<pubDate>Thu, 15 Oct 2009 21:17:55 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Schering-Plough Corporation]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=17778</guid>
		<description><![CDATA[Today, Dainippon Sumitomo and Sepracor (SEPR) have announced the successful completion of the initial share offering period, where almost 78.2% of Sepracor’s shares were tendered. The offer period has been extended to Oct 19, 2009, to enable other shareholders to tender their shares as well. As a reminder, in September, the Japanese pharmaceutical company Dainippon Sumitomo Pharma Co had announced a deal to acquire Sepracor at $23 per share or $2.6 billion. However, soon after the announcement, shareholders of Sepracor filed a suit in a Delaware court against the company, citing the offered price as inadequate. They were seeking the court’s intervention to stop the deal and pay damages. Additionally, certain aspects of the deal were against the interest of Sepracor’s shareholders. The deal included a $77.4 million termination fee ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/15/sepr-dainippon-sepracor-deal-emerges/17778/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Top Small-Cap Equity Funds &#8211; Mutual Fund Commentary</title>
		<link>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887</link>
		<comments>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887#comments</comments>
		<pubDate>Wed, 23 Sep 2009 20:09:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Charles River Laboratories International]]></category>
		<category><![CDATA[CRL]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15887</guid>
		<description><![CDATA[Today we are featuring top-performing “Small-Cap&#8221; equity mutual funds, which primarily invest in equity securities of companies that have market capitalizations of less than $2 billion. Investors can find such funds by checking out the entire list of the Zacks #1 Rank Small-Cap Equity Funds. 3 Solid Choices Buffalo Small Cap (BUFSX) seeks long-term growth of capital. The fund targets companies with individual market capitalizations of $2 billion or less at the time of initial purchase. The fund primarily invests in common stocks, preferred stocks, convertible preferred stocks warrants and rights of domestic small-cap companies. As of March 2009, its portfolio turnover was 15%. Kent Gasaway has been lead manager at the fund since its inception in April 1998. Previously, Gasaway spent 10 years with Waddell &#38; Reed Mutual Funds ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/sepr-top-small-cap-equity-funds-mutual-fund-commentary/15887/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMY) Bristol Myers Squibb Sells Indonesian Unit</title>
		<link>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384</link>
		<comments>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384#comments</comments>
		<pubDate>Wed, 16 Sep 2009 22:34:04 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Featured]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15384</guid>
		<description><![CDATA[Bristol Myers Squibb (BMY) yesterday announced that it would sell the Asian rights to its over-the-counter (OTC) drugs to Japan&#8217;s Taisho Pharmaceutical for $160 million. Taisho will also buy Bristol’s Indonesian unit, which manufactures and sells OTC and ethical pharmaceutical products, for $150 million. The deal is expected to close during the fourth quarter of this year. This is the latest in a series of deals signed by Bristol to focus on prescription drugs. Through this deal, the Japanese firm seeks to bolster its presence in markets where demand for self-medicating products is still growing. Furthermore, this transaction will help Japan&#8217;s biggest maker of non-prescription drugs to make its first full-fledged entry into Asia&#8217;s OTC drug market. The transaction  will enable Taisho to acquire certain product registrations, trademarks and related ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/16/bmy-bristol-myers-squibb-sells-indonesian-unit/15384/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Dainippon Sumitomo Pharma Acquires Sepracor</title>
		<link>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333</link>
		<comments>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333#comments</comments>
		<pubDate>Thu, 03 Sep 2009 20:46:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Schering-Plough Corp.]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>
		<category><![CDATA[SGP]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14333</guid>
		<description><![CDATA[Today morning, Japanese pharmaceutical company Dainippon Sumitomo Pharma Co., Ltd. confirmed that it signed a definitive agreement to buy U.S. pharmaceutical company Sepracor Inc. (SEPR). The deal has been valued at $23 per share or $2.6 billion. The market was abuzz with rumors yesterday regarding the potential takeover. The rumors led to a 26.46% increase in Sepracor’s stock price. Trading was halted in the afternoon with Sepracor shares closing at $22.80. This acquisition is the latest in a series of deals conducted by Japanese companies that are looking to tap the U.S. pharmaceutical market – the biggest in the world. Last year, we saw four such deals take place including Eisai’s acquisition of MGI Pharma, Takeda’s acquisition of Millennium Pharma and Shionogi’s acquisition of Sciele. Finally, Daiichi-Sankyo acquired a stake ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/03/sepr-dainippon-sumitomo-pharma-acquires-sepracor/14333/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MEDX) Top Delaware Funds &#8211; Mutual Fund Education</title>
		<link>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160</link>
		<comments>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160#comments</comments>
		<pubDate>Wed, 02 Sep 2009 20:22:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ABII]]></category>
		<category><![CDATA[Abraxis Bioscience Inc]]></category>
		<category><![CDATA[Medarex Inc]]></category>
		<category><![CDATA[MEDX]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=14160</guid>
		<description><![CDATA[Delaware Trend A (DELTX) seeks long-term capital appreciation by primarily investing in small, growth-oriented or emerging companies. The fund uses a bottom-up approach to create a portfolio and normally maintains its position in a stock until it fully achieves its growth potential. It analyzes price-to-earnings ratios, estimated growth rates, market capitalization and cash flows to determine the attractiveness of a company. Medarex Inc. (MEDX), Sepracor Inc. (SEPR) and Abraxis BioScience Inc. (ABII) are among the fund’s key holdings. Delaware International Value Equity A (DEGIX) was incepted in October 1991. The investment seeks long-term growth without undue risk to principal. The fund invests primarily in equity securities of issuers from foreign countries but may invest more than 25% of assets in the securities of issuers located in the same country. As ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/02/medx-top-delaware-funds-mutual-fund-education/14160/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SEPR) Sepracor Incorporated Doubled the Consensus Earnings Forecast</title>
		<link>http://www.stockbloghub.com/2009/08/27/sepracor-incorporated-doubled-the-consensus-earnings-forecast/13579</link>
		<comments>http://www.stockbloghub.com/2009/08/27/sepracor-incorporated-doubled-the-consensus-earnings-forecast/13579#comments</comments>
		<pubDate>Thu, 27 Aug 2009 20:52:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[SEPR]]></category>
		<category><![CDATA[Sepracor Incorporated]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=13579</guid>
		<description><![CDATA[Sepracor Inc (SEPR) shares are on a bullish run with a recent earnings report adding fuel to the fire. Company Description Sepracor develops safer, purer, and more effective drugs to improve on already existing pharmaceuticals. The company develops compounds to improve a therapy&#8217;s efficacy, side-effects, or both. Crushed Estimates On Jul 24 Sepracor reported second-quarter results that included an 11% pop in revenue, up to $326 million. Earnings per share came in at 72 cents, almost double the Zacks Consensus Estimate of 38 cents. This was the third consecutive surprise. Raising Guidance Management went on to raise full-year guidance Incorporatedreasing estimated revenue to $1.25 billion, give or take $25 million. Earnings per share are expected to be between $2.55 and $2.90, up from between $2.10 and $2.70. Estimtes Follow After ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/08/27/sepracor-incorporated-doubled-the-consensus-earnings-forecast/13579/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

